Press Releases

SITES - Press Release

Third-Quarter 2024 Business Review

bioMérieux, a world leader in the field of in vitro diagnostics, today releases its business review for the nine months ended September 30, 2024: Consolidated sales amounted to €2,871 million, representing an organic growth of +10.3% at constant exchange rates and scope of consolidation.

SITES - Press Release

bioMérieux receives CE-marking for VIDAS® VITAMIN B12 TOTAL, a blood test to measure total Vitamin B12 concentration

bioMérieux, a world leader in the field of in vitro diagnostics, announces the CE-marking of VIDAS® VITAMIN B12 TOTAL, an automated quantitative test for use on the VIDAS® immunoassay instruments, for the measurement of total Vitamin B12 concentration in human serum or plasma.

SITES - Press Release

First-Half 2024 Results

Marcy l’Etoile (France), September 5th, 2024 – The Board of Directors of bioMérieux, a world leader in the field of in vitro diagnostics, met on September 4th under the chairmanship of Alexandre Mérieux and approved the consolidated financial statements for the six months ended June 30, 2024.

SITES - Press Release

bioMérieux receives U.S. FDA Special 510(k) clearance and CLIA-waiver for its BIOFIRE® SPOTFIRE® Respiratory/Sore Throat (R/ST) Panel Mini

bioMérieux, a world leader in the field of in vitro diagnostics, today announces that its BIOFIRE® SPOTFIRE® Respiratory/Sore Throat (R/ST) Panel Mini has received U.S. Food and Drug Administration (FDA) Special 510(k) clearance and CLIA-waiver (Clinical Laboratory Improvement Amendments).

bioMérieux receives US FDA 510(k) clearance for its AST System VITEK® REVEAL™

bioMérieux, a world leader in in vitro diagnostics, today announces that its VITEK® REVEAL™ AST System, reporting results directly from positive blood cultures, has received U.S. Food and Drug Administration (FDA) 510(k) clearance.

SITES - Press Release

bioMérieux receives FDA 510(k) clearance of VIDAS® TBI (GFAP, UCH-L1), an innovative test to improve the assessment of patients with mild traumatic brain injury

bioMérieux, a world leader in the field of in vitro diagnostics, announces the U.S. FDA 510(k) clearance of VIDAS® TBI (GFAP, UCH-L1), a serum-based test to support the assessment of patients with mild traumatic brain injury (mTBI), including concussion.

SITES - Press Release

Malawi Ministry of Health, bioMérieux, and Pfizer Form Country’s First Multisectoral Collaboration to Help Address Antimicrobial Resistance

The Malawi Ministry of Health, bioMérieux, and Pfizer today announced a collaboration to advance Malawi’s first multisectoral initiative which aims to build public sector antimicrobial stewardship (AMS) capacity in infection prevention and control, diagnostics, surveillance, and to guide the appropriate use of antibiotics.

SITES - Press Release

bioMérieux presents its new 5-year strategic plan and its targets for profitable growth

bioMérieux, a world leader in the field in vitro diagnostics, is hosting today a Capital Markets Day in Paris. On this occasion, Pierre Boulud, Chief Executive Officer, together with members of the Executive Committee will present bioMérieux’s strategic plan, GO•28, the new chapter for the Company’s growth and development.

SITES - Press Release

First-Quarter 2024 Business Review

bioMérieux, a world leader in the field of in vitro diagnostics, today releases its business review for the three months ended March 31th, 2024.

SITES - Press Release

bioMérieux and Mérieux NutriSciences partner with key food industry players to launch a new collaborative data-driven model

bioMérieux and Mérieux NutriSciences jointly announce the launch of a new data-driven Trusted Third Party initiative, built with a group of global food industry partners to foster safe industry collaboration as well as better anticipate and prevent food safety risks.

SITES - Press Release

Dual 510(k) clearance and CLIA-waiver approval for the BIOFIRE® SPOTFIRE® R/ST Panel

bioMérieux, a world leader in the field of in vitro diagnostics, has received U.S. Food and Drug Administration (FDA) 510(k) clearance and Clinical Laboratory Improvement Amendments (CLIA) waiver approval for the BIOFIRE® SPOTFIRE® Respiratory/Sore Throat (R/ST) Panel.

SITES - Press Release

bioMérieux – 2023 Financial Results

Today bioMérieux released its 2023 financial results. Consolidated sales amounted to €3,675 million in 2023, up 6.6% like-for-like from €3,589 million in the prior year period.

Appointments

bioMérieux announces nomination of two new Executive Committee members to lead Medical Affairs and R&D

bioMérieux, a world leader in the field of in vitro diagnostics, announces the appointment of two new Executive Committee members: Dr. Charles K. Cooper as Executive Vice President, Chief Medical Officer, effective January 2nd, 2024; Céline Roger-Dalbert as Executive Vice President Research and Development, effective March 1st, 2024.

Mergers & Acquisitions

bioMérieux acquires LUMED to reinforce its software portfolio in the fight against antimicrobial resistance

bioMérieux, a world leader in the field of in vitro diagnostics, announces the acquisition of LUMED, a software company that has developed a clinical decision support system to help hospitals optimize antimicrobial prescriptions and monitor healthcare-associated infections.

Financial Information

Third-Quarter 2023 Business Review

bioMérieux, a world leader in the field of in vitro diagnostics, today releases its business review for the nine months ended September 30, 2023. Consolidated sales amounted to €2,668 million for the first nine months of 2023.